Here's the live share price of Aurobindo Pharma along with daily highs, lows, percentage changes and volume trends, and, all financial information.
Over the last 5 years, the share price of Aurobindo Pharma has gained 8.24% CAGR. Over the past year, the corresponding return has been -1.26%.
Aurobindo Pharma’s current P/E of 20.91x helps give context to how the market is valuing the stock based on recent earnings and growth expectations. Check out if this stock is part of our Breakout Stocks Screener.
Name | 1W(%) | 1M(%) | 3M(%) | 6M(%) | 1Y(%) | 3Y(%) | 5Y(%) |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | 3.70 | 12.01 | 13.01 | 2.16 | -1.26 | 38.49 | 8.24 |
| Sun Pharmaceutical Industries | 3.02 | 5.66 | 9.71 | 3.12 | 0.50 | 21.16 | 28.59 |
| Divi's Laboratories | -1.14 | -2.39 | 5.95 | -2.11 | 9.31 | 25.42 | 13.41 |
| Torrent Pharmaceuticals | -2.39 | 4.51 | 2.22 | 12.97 | 20.57 | 31.89 | 23.11 |
| Cipla | 0.32 | -6.99 | -1.56 | 2.21 | 3.63 | 11.33 | 15.50 |
| Dr. Reddy's Laboratories | 1.61 | -2.60 | 0.31 | 2.49 | 2.89 | 12.80 | 5.82 |
| Zydus Lifesciences | -2.20 | -7.17 | -5.94 | 2.07 | -1.76 | 32.83 | 16.67 |
| Lupin | -0.49 | 4.17 | 2.93 | -0.14 | -0.55 | 41.12 | 18.03 |
| Mankind Pharma | -2.27 | -9.47 | -10.83 | -13.23 | -13.49 | 15.98 | 9.30 |
| Alkem Laboratories | -0.55 | 3.20 | 6.37 | 7.73 | 3.76 | 22.96 | 16.48 |
| Abbott India | 0.09 | -1.08 | -10.50 | -3.57 | 8.81 | 14.71 | 14.20 |
| Biocon | 0.86 | 12.53 | 12.60 | 20.00 | 25.30 | 12.85 | -0.62 |
| Laurus Labs | -0.18 | 7.24 | 11.61 | 62.32 | 101.86 | 29.48 | 29.74 |
| Glenmark Pharmaceuticals | -0.33 | -0.64 | -5.39 | 28.06 | 23.36 | 64.77 | 30.70 |
| GlaxoSmithKline Pharmaceuticals | 0.36 | -8.40 | -10.73 | -10.82 | 3.23 | 24.32 | 11.12 |
| Ipca Laboratories | 7.38 | 13.38 | 3.98 | 0.26 | -8.40 | 18.38 | 6.92 |
| Anthem Biosciences | -6.31 | -11.57 | -21.41 | -11.97 | -11.97 | -4.16 | -2.52 |
| Ajanta Pharma | -1.73 | 3.57 | -6.81 | -4.16 | -14.19 | 27.06 | 19.78 |
| Gland Pharma | -3.80 | -8.34 | -9.31 | 18.86 | -0.81 | 0.93 | -0.63 |
| J B Chemicals & Pharmaceuticals | -3.79 | 3.57 | 1.25 | 5.19 | 5.07 | 18.75 | 30.42 |
Over the last one year, Aurobindo Pharma has declined 1.26% compared to peers like Sun Pharmaceutical Industries (0.50%), Divi's Laboratories (9.31%), Torrent Pharmaceuticals (20.57%). From a 5 year perspective, Aurobindo Pharma has underperformed peers relative to Sun Pharmaceutical Industries (28.59%) and Divi's Laboratories (13.41%).
| Day | SMA | EMA |
|---|---|---|
| 5 | 1,204.77 | 1,218.07 |
| 10 | 1,174.94 | 1,192.46 |
| 20 | 1,139.21 | 1,162.87 |
| 50 | 1,111.53 | 1,129.65 |
| 100 | 1,107.34 | 1,124.13 |
| 200 | 1,131.27 | 1,143.2 |
In the latest quarter, Aurobindo Pharma remained same as its previous close in promoter holding, while DII stake increased to 27.60%, FII holding fell to 14.21%, and public shareholding moved down to 6.37% compared to the previous quarter — reflecting a shift in investor sentiment across categories.
Fund Name | No. Of Shares | % of AUM | Amount Invested(in ₹ crore) |
|---|---|---|---|
| 1,33,44,745 | 1.7 | 1,519.83 | |
| 65,00,000 | 2.08 | 740.29 | |
| 59,69,000 | 7.97 | 679.81 | |
| 52,61,125 | 1.83 | 599.19 | |
| 51,74,277 | 4.74 | 589.3 | |
| 43,05,998 | 7.62 | 490.41 | |
| 42,94,483 | 5.25 | 489.1 | |
| 32,30,588 | 0.64 | 367.93 | |
| 30,30,611 | 5.01 | 345.16 | |
| 27,22,312 | 0.29 | 310.04 |
* Excluding Index & Arbitrage Funds
| Price | (%) As on Invalid Date IST |
| Open Interest | (%) |
| High | |
| Low | |
| Open | |
| Close | |
| Contract Traded | |
| Turnover (in lakhs) |
Date Time | Announcement |
|---|---|
| Nov 14, 2025, 9:37 PM IST | Aurobindo Pharma - Completion Of US FDA Inspection At Unit II Of Eugia Pharma Specialities Ltd., Bhiwadi, A Wholly Owned Subs |
| Nov 14, 2025, 5:20 PM IST | Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| Nov 14, 2025, 4:02 PM IST | Aurobindo Pharma - Classification Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiar |
| Nov 11, 2025, 10:32 PM IST | Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript |
| Nov 06, 2025, 1:34 AM IST | Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 10933.30 Cr. and Equity Capital is Rs. 58.08 Cr. for the Year ended 31/03/2025.
The share price of any company is dynamic and keeps changing depending on the trade initiated. The shares have a fixed opening rate and closing rate. The share price for Aurobindo Pharma is ₹1,232.15 as on Nov 19, 2025.
The Aurobindo Pharma is operating in the Pharmaceuticals and health care Sector. It is classified as a Largecap stock on the BSE.
The market cap of Aurobindo Pharma is ₹71,563.47 Cr as on Nov 19, 2025.
Today’s highest and lowest price of Aurobindo Pharma are ₹1,244.00 and ₹1,228.85.
The 52-week high/low is the highest and lowest price at which Aurobindo Pharma stock has traded in the past 52-week or nearly a year. The 52-week high of Aurobindo Pharma is ₹1,364.95 and 52-week low of Aurobindo Pharma is ₹994.35 as on Nov 19, 2025.
The Aurobindo Pharma has shown returns of -0.6% over the past day, 12.01% for the past month, 13.01% over 3 months, -1.26% over 1 year, 38.49% across 3 years, and 8.24% over 5 years.
P/E ratio of and PB ratio of Aurobindo Pharma are 20.91 and 2.19 on Nov 19, 2025. While the company gives a dividend yield of 0.00 per annum.